Recently, Medtronic announced a collaboration with Arecor (a biopharmaceutical company) to develop a new type of insulin, which can be used in conjunction with the new insulin pump that Medtronic is currently developing. The new insulin pump will be located subcutaneously rather than on the skin surface.

This research collaboration aims to develop a new type ofHigh Concentration, Heat StableInsulin,Can minimize the need for pump maintenance interventions。Currently in the early stages of development, clinical trials are still needed.

# Medtronic — Diabetes Business

Medtronic's diabetes business includesCGMS, Insulin Pump, Insulin Injection PenAndData Management SystemA complete set of solutions, with the goal of creating a leading closed-loop artificial pancreas.

Medtronic New GenerationInsulin Pump MiniMed 780G,CGM Simplera SystemIs the core product of Medtronic's diabetes strategy.

• Medtronic MiniMed™ 780G System

In August 2023, the Medtronic MiniMed™ 780G system received FDA approval.

The only system that adopts dietary testing technology,ToolWith 5-minute automatic correction function。

This means that it will automatically bolus in cases where users occasionally forget to bolus or underestimate the carbohydrate content of a meal.

Insulin for blood glucose correction.

• CGM Simplera System

Simplera is the successor to Guardian 4 and requires no calibration. The sensor and transmitter are integrated into one unit, which can be attached to the skin with a single click, eliminating the need for excessive adhesion.

The company's current product portfolio includes:Ultra-fast insulin; Ultra-concentrated rapid-acting insulin; Glucagon injection.

The main product R&D information is as follows:

Arestat™ consists of a series of innovative and proprietary biologics technology platforms that enhance the properties of proteins and peptides both in vivo and in vitro.

At the same time, it can concentrate biomolecules and maintain the thermal stability, low viscosity, and ideal PK/PD characteristics of the improved formulation.

Among them, AT278 is the first ultra-concentrated rapid-acting insulin candidate drug developed based on Arecor's Arestat™ technology, aiming toOvercome issues such as slowed absorption and delayed hypoglycemic curve caused by increased insulin concentration.

"Our leading position in this field has been demonstrated through our world-class ultra-fast-acting clinical development programs (AT278 and AT247). At the same time, the rise of innovative delivery devices, including more durable and miniaturized pumps, further underscores our advancements."

We are delighted to play our part in this progress, developing a highly differentiated insulin that has the potential to transform the treatment of an extremely vulnerable patient population. This collaboration is one of many we hope to achieve to further enhance the benefits of these next-generation devices."

Currently focusing on developing enhanced products for insulin and anti-infective drugs.

2024 Global MedTech List：Award Recruitment in Progress

2023 Global Medical Technology Industry Contribution Award

Global Medical Technology Industry Map: International Leaders

Cardiovascular:Medtronic｜Johnson & Johnson J&JMedTech｜BD Medical｜Boston Scientific｜Edwards Lifesciences｜Abbott｜Orthopedics:Medtronic｜Johnson & Johnson J&JMedTech｜Stryker｜Smith & Nephew S&N｜Zimmer Biomet Ophthalmology:ESSILOR｜Alcon｜Carl Zeiss Medical |Topcon｜Cooper Medical Imaging:Siemens Healthineers｜Philips Medical｜GE Healthcare｜Olympus

Global Medical Technology Industry Map: Chinese Listed Companies

Mindray Medical|JIUAN Medical|Weigao Group|DaAn Gene|Lepu Medical|Medtronic |Shinva Medical|United Imaging Healthcare|Oriental Biotech|Yuwell Medical|Kehua Bio-engineeringIntco Medical|SaintDiagnostics|Guo Ke Heng Tai|DaAn Gene|Ying Tai Medical

Global Medical Technology Industry Map: Industrial Clusters

Medical Alley, Minnesota, USA | Warsaw, Indiana, USA | Massachusetts, USA | Costa Rica | NetherlandsEindhoven | U.S. Route 128 Tech Corridor | Japan | United StatesPuerto Rico | Ireland | ItalyMilandola | Erlangen, Germany | GermanyTuttlingen | Tonglu

Editor-in-Chief | Zhao Qing Reviewed by | Yi He